To the Editor We read with great interest the article by Palma and colleagues1 published in JAMA Oncology. Unexpectedly, stereotactic ablative radiotherapy (SABR) resulted in a pathologic complete response (pCR) rate of only 60%; this rate is lower than the local control (LC) rate of SABR alone, which is generally higher than 90%.2 The authors explained that the limitation of hematoxylin-eosin staining technology and short waiting time between SABR and surgery may have contributed to underestimation of the pCR rate.1 However, more issues still need to be discussed.
Liu J, Zhang Y, Yue J. Analysis of Pathologic Complete Response 10 Weeks After Radiotherapy—A Radiobiological Sin. JAMA Oncol. Published online July 03, 2019. doi:10.1001/jamaoncol.2019.1890
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: